Daniel D. Shoemaker

2017

In 2017, Daniel D. Shoemaker earned a total compensation of $798.3K as Chief Scientific Officer at Fate Therapeutics, a 12% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$80,194
Option Awards$365,604
Salary$352,500
Total$798,298

Shoemaker received $365.6K in option awards, accounting for 46% of the total pay in 2017.

Shoemaker also received $80.2K in non-equity incentive plan and $352.5K in salary.

Rankings

In 2017, Daniel D. Shoemaker's compensation ranked 10,043rd out of 14,666 executives tracked by ExecPay. In other words, Shoemaker earned more than 31.5% of executives.

ClassificationRankingPercentile
All
10,043
out of 14,666
32nd
Division
Manufacturing
3,882
out of 5,772
33rd
Major group
Chemicals And Allied Products
1,359
out of 2,075
35th
Industry group
Drugs
1,103
out of 1,731
36th
Industry
Biological Products, Except Diagnostic Substances
198
out of 313
37th
Source: SEC filing on March 16, 2018.

Shoemaker's colleagues

We found two more compensation records of executives who worked with Daniel D. Shoemaker at Fate Therapeutics in 2017.

2017

J Wolchko

Fate Therapeutics

Chief Executive Officer

2017

Christopher Storgard

Fate Therapeutics

Chief Medical Officer

News

You may also like